1839-17-4

Usage

Uses

Used in Pharmaceutical Synthesis:
4-N-METHYLPYRIDINE-3,4-DIAMINE is used as a precursor in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic properties.
Used in Agrochemical Production:
In the agrochemical industry, 4-N-METHYLPYRIDINE-3,4-DIAMINE is used as a precursor to create compounds that can protect crops from pests and diseases, enhancing agricultural productivity.
Used in Chemical Industry Materials:
4-N-METHYLPYRIDINE-3,4-DIAMINE is utilized in the production of various materials due to its reactive nature, which allows for the creation of a wide range of chemical products.
Used as a Corrosion Inhibitor:
4-N-METHYLPYRIDINE-3,4-DIAMINE is used as a corrosion inhibitor in industrial applications to protect metals from degradation, extending the lifespan of equipment and structures.
Used as an Anti-Microbial Agent:
In various industries, 4-N-METHYLPYRIDINE-3,4-DIAMINE serves as an anti-microbial agent to control the growth of microorganisms, which is crucial for maintaining hygiene and preventing spoilage.
Used in Organic Reactions:
As a reactant in organic reactions, 4-N-METHYLPYRIDINE-3,4-DIAMINE is instrumental in facilitating chemical processes that lead to the formation of desired products in the synthesis of various compounds.
Used in Dye and Pigment Production:
4-N-METHYLPYRIDINE-3,4-DIAMINE is used in the production of dyes and pigments for its ability to contribute to the coloration and stability of these products in different applications.
Used in Polymer Production:
4-N-METHYLPYRIDINE-3,4-DIAMINE is also used in the synthesis of polymers, where it can influence the properties of the final polymeric materials, such as strength, flexibility, and durability.
Used in Medicine:
In the medical field, 4-N-METHYLPYRIDINE-3,4-DIAMINE has applications in the treatment of neurological disorders, potentially offering therapeutic benefits to patients.
Used in Hair Dye Formulation:
As an ingredient in hair dyes, 4-N-METHYLPYRIDINE-3,4-DIAMINE contributes to the coloring effect and may enhance the performance of hair dye products.
It is important to handle and use 4-N-methylpyridine-3,4-diamine with care due to its potential health and environmental risks, ensuring safe practices in its application across various industries.

Upstream product

• 1633-41-6 3-nitro-4-methylaminopyridine 
• 13091-23-1 4-chloro-3-nitropyridine 
• 31872-62-5 4-methoxy-3-nitro-pyridine 

Downstream Products

• 45880-13-5 1,2-dimethylimidazo<4,5-c>pyridine 
• 675581-77-8 2-ethyl-1-methyl-1H-imidazo[4,5-c]pyridine 
• 5028-32-0 1-methylimidazo<4,5-c>pyridine 
• 87359-60-2 2-(2,4-dimethoxyphenyl)-1-methylimidazo<4,5-c>pyridine dihydrochloride 
• 89734-93-0 2-phenyl-1-methylimidazo<4,5-c>pyridine 
• 143361-85-7 4-(1-Methyl-1H-imidazo[4,5-c]pyridin-2-yl)-phenylamine 
• 80675-88-3 2-Methoxy-6-(1-methyl-1H-imidazo[4,5-c]pyridin-2-yl)-phenol 
• 80675-89-4 2-Methoxy-4-(1-methyl-1H-imidazo[4,5-c]pyridin-2-yl)-phenol 
• 80675-91-8 2-(3,4-Dimethoxy-phenyl)-1-methyl-1H-imidazo[4,5-c]pyridine 
• 80675-87-2 Dimethyl-[4-(1-methyl-1H-imidazo[4,5-c]pyridin-2-yl)-phenyl]-amine 
• 145254-30-4 N-(4-methylamino-3-pyridyl)-N'-cyclohexylthiourea 
• 35251-84-4 1,4-dihydro-pyrido[3,4-b]pyrazine-2,3-dione 
• 7397-68-4 1,3-dihydro-2H-imidazo[4,5-c]pyridin-2-one 
• 40423-52-7 1-methyl-1,3-dihydro-2H-imidazo<4,5-c>pyridin-2-one 

Relevant academic research and scientific papers

ANTI-FIBROTIC PYRIDINONES

This application relates to polycyclic compounds with a pyridinone or pyridinone derivative core including, substituted pyridinones, 5,6- and 6,6- bicyclic heterocycles and substituted pyridine-thiones. This application also discloses methods of preparing these polycyclic compounds, pharmaceutical compositions and medicaments comprising said compounds and methods to treat, prevent or diagnose diseases, disorders or conditions associated with fibrosis.

COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS

The present invention relates to new medicament combinations which contain in addition to one or more PDE4-inhibitors (1) at least one EP4 receptor antagonist (2), as well as the use thereof for the treatment of preferably respiratory complaints such as particularly COPD, chronic sinusitis and asthma. The invention relates in particular to those medicament combinations which contain, in addition to one or more, preferably one, PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one EP4 receptor antagonist (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS

The present invention relates to new drug combinations which contain in addition to one or more PDE4-inhibitors at least one NSAID (=non-steroidal anti-inflammatory drug) (2), processes for preparing them and their use in treating in particular respiratory complaints such as for example COPD, chronic sinusitis and asthma. The invention particularly relates to those drug combinations which contain, in addition to one or more, preferably one PDE4 inhibitor of general formula 1 wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 have the meanings given in claim 1, at least one NSAID (2), the preparation thereof and the use thereof for the treatment of respiratory complaints.

METHODS OF USING DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY (ADP-RIBOSE)POLYMERASE (PARP)

Provided herein are methods of treating cancer comprising administering a topoisomerase inhibitor, temozolomide, or a platin in combination with a Compound of Formula (I) or Formula (II), where the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein.

SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES

The invention relates to new piperidino-dihydrothienopyrimidines of formula 1, as well as pharmacologically acceptable salts thereof, wherein X is SO or SO2, but preferably SO, and wherein R1, R2, R3 and R4 may have the meanings given in claim 1, as well as pharmaceutical compositions which contain these compounds. These new piperidino-dihydrothienopyrimidines are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers.

DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP)

A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity.

AZABENZIMIDAZOLYL COMPOUNDS

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

Structure-guided design of substituted aza-benzimidazoles as potent hypoxia inducible factor-1α prolyl hydroxylase-2 inhibitors

We report the structure-based design and synthesis of a novel series of aza-benzimidazoles as PHD2 inhibitors. These efforts resulted in compound 22, which displayed highly potent inhibition of PHD2 function in vitro.

3-(Imidazolyl methyl)-3-aza-bicyclo[3.1.0]hexan-6-yl)methyl ethers: A novel series of mGluR2 positive allosteric modulators

The synthesis and structure-activity relationship (SAR) of a novel series of 3-(imidazolyl methyl)-3-aza-bicyclo[3.1.0]hexan-6-yl)methyl ethers, derived from a high throughput screening (HTS), are described. Subsequent optimization led to identification of potent, metabolically stable and orally available mGluR2 positive allosteric modulators (PAMs).

(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: A novel class of potent MSK-1-inhibitors

A novel series of imidazo[4,5-c]pyridines bearing a 1,2,5-oxadiazol-3- ylamine functionality has been developed. These are potent inhibitors of mitogen and stress-activated protein kinase-1.